Cite
Meegdes M, Ibragimova KIE, Lobbezoo DJA, et al. The initial hormone receptor/HER2 subtype is the main determinator of subtype discordance in advanced breast cancer: a study of the SONABRE registry. Breast Cancer Res Treat. 2022;doi: 10.1007/s10549-021-06472-5.
Meegdes, M., Ibragimova, K. I. E., Lobbezoo, D. J. A., Vriens, I. J. H., Kooreman, L. F. S., Erdkamp, F. L. G., Dercksen, M. W., Vriens, B. E. P. J., Aaldering, K. N. A., Pepels, M. J. A. E., van de Winkel, L. M. H., Tol, J., Heijns, J. B., van de Wouw, A. J., Peters, N. A. J. B., Hochstenbach-Waelen, A., Smidt, M. L., Geurts, S. M. E., & Tjan-Heijnen, V. C. G. (2022). The initial hormone receptor/HER2 subtype is the main determinator of subtype discordance in advanced breast cancer: a study of the SONABRE registry. Breast cancer research and treatment, . https://doi.org/10.1007/s10549-021-06472-5
Meegdes, Marissa, et al. "The initial hormone receptor/HER2 subtype is the main determinator of subtype discordance in advanced breast cancer: a study of the SONABRE registry." Breast cancer research and treatment vol. (2022). doi: https://doi.org/10.1007/s10549-021-06472-5
Meegdes M, Ibragimova KIE, Lobbezoo DJA, Vriens IJH, Kooreman LFS, Erdkamp FLG, Dercksen MW, Vriens BEPJ, Aaldering KNA, Pepels MJAE, van de Winkel LMH, Tol J, Heijns JB, van de Wouw AJ, Peters NAJB, Hochstenbach-Waelen A, Smidt ML, Geurts SME, Tjan-Heijnen VCG. The initial hormone receptor/HER2 subtype is the main determinator of subtype discordance in advanced breast cancer: a study of the SONABRE registry. Breast Cancer Res Treat. 2022 Jan 13; doi: 10.1007/s10549-021-06472-5. Epub 2022 Jan 13. PMID: 35025003.
Copy
Download .nbib